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ABSTRACT
Objective: Carotid sinus hypersensitivity (CSH) is
common in older people. The authors hypothesise that
patients with CSH have a higher mortality than
a geographically, age-matched older cohort.
Design: A retrospective cohort study compared to
geographical and age-matched data from the Ofﬁce of
National Statistics.
Setting: Specialist clinic in tertiary centre.
Patients: 1504 patients with CSH were identiﬁed from
a single syncope outpatient assessment service
between 1990 and 2001.
Interventions: Vital status was conﬁrmed, and death
certiﬁcates were sought for all deceased patients up to
2003.
Main outcome measures: KaplaneMeier survival
curves were analysed within the cohort according to
three different subtypes of CSH. Standardised
mortality rates (SMRs) were determined using
geographical and age-matched data from the Ofﬁce of
National Statistics.
Results: There was no difference between CSH
patients and the general population in SMRs for all
causes, or for cerebrovascular or cardiovascular
deaths. There was no difference in survival between
the three subtypes of CSH (p¼0.2) within the study
cohort.
Conclusion: CSH is not associated with a higher
mortality than the general population, and there are no
differences in mortality between the three subtypes of
CSH. This conﬁrms earlier ﬁndings and reinforces the
neutral effect of CSH on mortality.
INTRODUCTION
Carotid sinus hypersensitivity (CSH) is
a disease of older people, with a prevalence
of between 25% and 48% in patients referred
to hospital for unexplained syncope, falls or
dizziness.
1e3
Three subtypes of carotid sinus hypersensi-
tivity have been described: cardioinhibitory
(CICSH), diagnosed if carotid sinus massage
(CSM) results in three or more seconds of
asystole; vasodepressor (VDCSH), diagnosed
if carotid sinus massage results in a drop in
systolic blood pressure of 50 mm Hg ormore;
and mixed CSH, diagnosed if both cardi-
oinhibition and vasodepression are present.
Syncope accounts for 3% of attendances at
Accident and Emergency departments and
1% of admissions to a general hospital in the
USA.
4 Falls account for approximately 10%
of visits to the Accident and Emergency
department and 6% of admissions to
a general hospital.
56Of those admitted to
hospital following a fall, only about 50% are
alive 1 year later. Accidents are the ﬁfth
leading cause of death in older people, and
falls constitute two-thirds of these accidental
deaths,
7 and are the commonest cause of
injury-related death in persons over 75 years
of age.
8 CSH has a high incidence of
morbidity, as it may lead to syncope, falls and
accidents: approximately one in 10 falls leads
to serious injury such as hip fractures, other
fractures, subdural haematoma, soft-tissue
injury or head injury.
591 0There is also an
association between CSH and dementia.
11
Despite these associations with signiﬁcant
markers of frailty and morbidity, there is
limited evidence to date describing the
implications of the presence of CSH for older
people in terms of mortality.
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ARTICLE SUMMARY
Article focus
- Mortality rates in patients with CSH compared
with age and geographically matched controls.
- Mortality rates compared between the three CSH
subtypes, vasodepressor, cardioinhibitory and
mixed.
Key messages
- This is the largest known cohort of patients with
CSH to date.
- This conﬁrms previous ﬁndings by smaller
studies.
- CSH has no effect on mortality.
Strengths and limitations of this study
- This is a retrospective study.
- The sample size is large.
- It was not possible to address morbidity, as there
was no control group. The control group for
mortality was taken from the Ofﬁce of National
Statistics.
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Open Access ResearchBrignole et al followed up 262 patients identiﬁed over
a 6-year period who presented with syncope and were
found to have CSH as a cause of their symptoms. The
follow-up period was between 2 and 8 years (mean 44 6
24 months). The control group was 55 patients who had
unexplained syncope, matched for age and sex. The
overall mortality rate for the CSH patients was 7.3 per
100 person-years, compared with 5.8 per 100 person-
years in the control group. The mortality rate after
5 years was 34% in the CSH group, compared with 27%
in the control group. The standardised mortality rate
(SMR) of the general population with a similar age and
sex distribution was 8 per 100 person-years. The
mortality rate in the CSH group was not inﬂuenced by
CSH subtype.
12 Similar ﬁndings were reported by Sutton
et al; the 5-year mortality rate was 36%.
13
Engel hypothesised that death may result from
prolonged asystole often following severe vasodepressor
syncope, or that prolonged asystole could indirectly
trigger malignant tachyarrhythmias.
14 This study aims to
reassess the mortality rate in a larger consecutive cohort
of patients with symptomatic CSH compared with age
and geographically matched statistics from the Ofﬁce of
National Statistics.
METHODOLOGY
One thousand ﬁve hundred and four patients with CSH
were identiﬁed retrospectively from a single Syncope
Service in the North East of England over a 10-year
period. The service assessed patients referred either by
GPs or by hospital physicians and was an outpatient
facility. All patients aged 50 or over, referred for investi-
gation of syncope or falls routinely undergo CSM using
phasic BP recording equipment (Finometer/Finapres)
in addition to orthostatic BP measurements and a surface
ECG. The diagnosis of CSH was conﬁrmed by reviewing
hard copies of blood pressure and heart-rate tracings.
The vital status of each patient was checked on the
hospital Patient Administration System PAS) and via
contact with the patients’ General Practitioners (GPs).
The Ofﬁce of National Statistics (ONS) records all deaths
in the UK. Death certiﬁcates for deceased patients were
obtained from the ONS. Recorded death-certiﬁcation
details included date of death, place of death, address of
last known residence, and underlying cause of death.
The cause of death was classiﬁed into ischaemic heart
disease, cerebrovascular disease, other circulatory
diseases (including hypertensive heart disease, valvular
heart disease, cardiac arrhythmias, ill-deﬁned heart
disease) and other causes (non-cardiovascular/non-
cerebrovascular) using the International Code of
Disease, Nineth Revision.
15
Data for the control group were compiled from
population statistics published by the ONS.
16 Mortality
tables were identiﬁed from the North East (combining
data from Tyne and Wear and Northumberland) and
matched to the study cohort for age, sex and year of
death. Figures were extracted from the ONS tables for
death due to all causes, ischaemic heart disease and
cerebrovascular disease.
Statistical analysis
The ages of the groups of patients who were alive or
dead were analysed at two points: (1) at the time of
diagnosis of CSH and (2) on the date at which the
patient was last identiﬁed. This was the age at death for
the deceased patients, and the age when they were
conﬁrmed to be alive by the GP for the living patients
(known as ‘last known age’).
Survival analysis between the three subtypes of CSH
was tested by the KaplaneMeier method. KaplaneMeier
survival curves represent the cumulative probability of an
individual remaining free of an endpoint, in this case,
death.
Cause of death was compared with mortality statistics
from the ONS, which were matched for age, sex and
geographical location. Standardised mortality rates for
all-cause mortality and mortality due to ischaemic heart
disease and cerebrovascular disease were calculated (see
below). To ensure an accurate comparison with the data
from the ONS, the number of deaths was stratiﬁed by
age (divided into 5-year age-bands) and by the year in
which the death occurred. It was not possible to further
stratify by gender because of insufﬁcient sample size
within each age group and year. The total number of
patients within the study cohort changed every year: the
cohort was identiﬁed retrospectively, and thus all
patients diagnosed as having CSH between 1990 and 31
December 2001 were included. Thus, patients were
entering the cohort every year, but some patients were
dying each year, and the length of follow-up varied
according to the year of diagnosis. This meant the total
number of patients within the cohort was different each
year. In population statistics from the ONS, the popula-
tion is calculated from a midyear estimate based on the
latest census information and total number of deaths. In
order to make a comparison between the study cohort
and the general population of the North East, the
number of person years observed (PYOs) within the
study cohort for each year was calculated. Person years
calculates the number of people living for each year, that
is, the proportion of each year an individual is living
after they entered the study calculated as a decimal of
a year (eg, a person who entered the study on 01.01.1990
and died in June 1992, would have 1 PYO for 1990, 1
PYO for 1991, and 0.5 PYO for 1992). The total PYOs
were calculated for the entire cohort (n¼1504) and then
stratiﬁed by 5-year age-bands and years.
Total deaths for all cause mortality, IHD and CVD
deaths in 1991e2003 were recorded for the general
population from the North East, and also stratiﬁed by
5-year age bands. Crude death rates were then calculated
for both the study population and the general popula-
tion in the North East. The crude death rate in the study
population is the total number of deaths divided by the
number of PYOs for each age and year. The death rate
for the study cohort is expressed as death rate per 1000
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Mortality in CSHPYOs (the crude rate multiplied by 1000). Similarly, the
crude death rate in the general population is the total
number of deaths divided by the number of people
within the population for each age and year. The death
rate for the general cohort is expressed as death rate per
1000 population at risk (again, the crude rate multiplied
by 1000).
To account for the differing age structures within the
two populations, the SMR was calculated. The indirect
method of standardisation was used comparing the
expected number of deaths calculated from the general
population with the observed number of deaths in the
study cohort. The expected number of deaths was
calculated by using the age structure of the study group;
the PYOs in the study cohort were multiplied by the
crude death rate in the North East population. This
ﬁgure was then rounded up to whole numbers.
A SMR of less than 1 suggests the study cohort has
fewer deaths than the expected ﬁgure in the general
population; a ﬁgure of greater than 1 suggests there are
more deaths in the study cohort than the general
population.
RESULTS
One thousand ﬁve hundred and four patients were
initially identiﬁed from the Syncope Service with deﬁnite
CSH (median age 76.7 years, 59% female). Six hundred
and seventy-eight (45%) patients were VDCSH, 427
(28%) CICSH and 399 (26%) mixed CSH.
Three hundred and forty-ﬁve patients (23%) of the
1504 were recorded as deceased on the PAS. A further
240 deceased patients were identiﬁed by telephoning
GPs, resulting in a total of 585 (40%) dead and 910
(60%) living patients. The vital status of nine patients
was untraceable (ﬁgure 1). During the study period,
a further 11 patients died and were included in subse-
quent mortality analysis. The date of death was
untraceable in 10 patients: thus survival analysis was
completed on 1485 patients (99%). Survival rates for
patients with CICSH, VDCSH and Mixed CSH were
similar (p¼0.2). The median survival time for CICSH
was 8 years (95% CIs 7.3 to 8.7 years); the median
survival time for VDCSH was 7 years (95% CIs 6.4 to
7.4 years), and the median survival time for mixed CSH
was 8 years (95% CIs 7.4 to 8.6 years) (ﬁgure 2).
There was no difference between the numbers of
deaths due to all causes in patients with CSH compared
with the general population of the North East in any year
with the exception of 2002 and 2003 (SMR 1.4 (95% CI
1.1 to 1.7) and SMR 1.8 (95% CI 1.1 to 2.9); table 1).
The year-on-year point estimates predictably suggest
these ratios move from under one to over one over time
as the cohort matures. The number of deaths in the
study cohort and the control group increased with age
for all causes, ischaemic heart disease (IHD) and cere-
brovascular disease (CVD). There was no difference in
any year between the numbers of deaths due to IHD or
CVD in patients with CSH compared with the control
group.
Death certiﬁcates were available for 581 of 596
requested (98%). Death due to non-cardiovascular/non-
cerebrovascular causes (classiﬁed as ‘other causes’) was
most common (324 patients (56%)). Of cardiovascular
causes, 117 patients (20.1%) died of ischaemic heart
disease; 96 patients (16.5%) died from stroke disease,
and 44 patients (7.6%) died from other circulatory
diseases. Diseases of the respiratory system were the most
common cause of death within the ‘other causes’ cate-
gory, affecting 110 patients (19%). Nineteen patients
(3%) were coded as dying from mental disease, and all
were suffering from dementia. A further 16 patients
(3%) were coded as dying from ‘symptoms, signs and ill-
deﬁned conditions’ and the death certiﬁcates in all these
cases listed causes describing senescence such as ‘old
age’ or ‘frailty.’
Figure 1 Vital status of the cohort at the beginning of study.
Figure 2 KaplaneMeier survival curve for the study cohort
comparing subtypes of carotid sinus hypersensitivity (n¼1485).
CICSH, cardioinhibitory carotid sinus hypersensitivity; CSH,
carotid sinus hypersensitivity; VDCSH, vasodepressor carotid
sinus hypersensitivity. There is no signiﬁcant difference in
mortality between the three CSH subtypes.
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Mortality in CSHDISCUSSION
This paper has shown that, in a large cohort study of
1500 patients, mortality is similar to age and geograph-
ically matched controls. It conﬁrms earlier ﬁndings
from smaller cohorts published by Sutton
13 and
Brignole.
12 The methodologies for analysis of survival
rates between the subtypes of CSH in this study and
Brignole’s study are similar, and Brignole has kindly
given permission for the data from his study to be
published in this paper for comparison (ﬁgure 3).
Figure 2 from this study and ﬁgure 3 from Brignole’s
study show similar KaplaneMeier curves for the three
CSH subtypes and conﬁrm that there is no difference
in survival rates between CICSH, VDCSH and Mixed
CSH.
In Brignole’s control group, the morbidity (including
rate of stroke, myocardial infarction and atrial ﬁbrilla-
tion) over a 5-year follow-up period was comparable with
that of the CSH group suggesting a neutral effect of CSH
on morbidity. This ﬁnding could not be conﬁrmed in our
cohort, as there was no control group. However, more
recent evidence also reinforces the possibility that for
certain individuals, having CSH may be entirely benign:
in 2006, a community-based study of individuals aged 65
and over who were asymptomatic for falls, syncope and
dizziness found that CSH was prevalent in 35%.
17 This
raised the possibility that CSH was not a pathological
diagnosis but rather an age-related phenomenon. More
recently, Tan et al
18 have also discussed this possibility
following their ﬁndings that only 25% of patients (age
range 38e98 years; mean age 71.5 years) presenting with
classical symptoms for CSH (syncope, drop attacks and
unexplained falls) were found to have CSH following
CSM. This ﬁgure is lower than the ﬁgure observed in
Kerr’s study of asymptomatic community-dwelling
patients over 65 and may be explained by referral bias
and demographic differences but adds support for the
hypothesis that CSH is an age-related physical entity
rather than a causal mechanism for certain symptoms
such as syncope, falls and drop attacks.
If this is true, then an increase in mortality in patients
with CSH would not be expected. The standardised
mortality ratio of patients in the study cohort for
death by all causes was increased in 2002 and 2003,
but there was no increase from 1991 to 2001. This is
likely to reﬂect small sample sizes rather than true clin-
ical signiﬁcance. It may also be a reﬂection of the
method of mortality analysis and the comparative
population.
The study cohort was generated from a specialist clinic
in a teaching hospital. This may have introduced bias.
Retrospective data collection also leads to further bias
due to poorly recorded information that was not
collected with clear questions in mind.
In summary, this paper conﬁrms previous ﬁndings that
there is no increase in mortality rates in patients with
CSH compared with the general population. Despite this
ﬁnding, it is important to remember that management
goals for patients with CSH should remain the same:
patients with CICSH and syncope in particular beneﬁt
from pacing, and this will add greatly to a reduction in
symptoms and morbidity.
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